Soligenix, Inc.

Princeton, NJ

UEI
GVD4XBVYD9J5
CAGE
44FA7
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
29 Emmons Dr, Princeton, NJ 08540, USA
Website
soligenix.com
Founded
1987
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

Award Agency Obligated Awarded
Development of vaccine formulations effective against niaid priority pathogens HHSN272201400039C National Institute of Allergy and Infectious Diseases (NIH) $21,224,049
Development of medical countermeasures to mitigate or treat the gastrointestinal acute radiation syndrome after a… HHSN272201300030C National Institute of Allergy and Infectious Diseases (NIH) $7,041,180
Orbeshield development program HHSO100201300023C Office of the Assistant Secretary for Preparedness and Response $10,823,411

Grant awards

Award Agency Obligated Awarded
Thermostabilized subunit glycoprotein vaccine platform: immune characterization of an emulsified adjuvant with… R44AI157593 National Institute of Allergy and Infectious Diseases (NIH) $5,479,476
Dusquetide for the treatment of oral mucositis in the pediatric population R43DE028769 National Institute of Dental and Craniofacial Research (NIH) $150,000
Phase 3 study of SGX301 and fluorescent light for cutaneous t cell lymphoma R44CA210848 National Cancer Institute (NIH) $1,500,000
SGX942 to decrease oral mucositis after chemoradiation for head and neck cancer R44DE024032 National Institute of Dental and Craniofacial Research (NIH) $1,464,817
SGX942 to decrease oral mucositis after chemoradiation for head and neck cancer R43DE024032 National Institutes of Health $225,000

Latest 5 listed here. See the rest on GovTribe.

Grant subawards

Prime recipient Prime award Amount Awarded
The Trustees Of The University Of Pennsylvania Soligenix is committed to supporting Ellen Kim, MD and Principal Investigator of this application that seeks to conduct the clinical trial, RW-HPN-MF-01,… R01FD007262 $290,243

Similar vendors

Vendor Location Primary NAICS
Antagen Biosciences Inc. UEI HXD6EFH2ND57 Canton, MA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Tendel Therapies Inc. UEI JA9BDUH73852 Kensington, CA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Versatope Therapeutics Inc. UEI VSMPM3EGYYA6 Lowell, MA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Inimmune Corp UEI EF8AMXMGG8W5 Missoula, MT 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Lumen Bioscience, Inc. UEI E9UJDT3BFUQ5 Seattle, WA 541714 Research and Development in Biotechnology (except Nanobiotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Soligenix, Inc. is a late stage biopharmaceutical company dedicated to developing and commercializing products that treat rare diseases, life-threatening side effects of cancer treatments, serious gastrointestinal diseases, and vaccines for bioterrorism agents. It is a for-profit organization registered as a self-certified small disadvantaged business.

Through prime federal grant awards, Soligenix, Inc. has conducted research on a thermostabilized subunit glycoprotein vaccine platform, involving immune characterization of an emulsified adjuvant with SARS-CoV-2 spike protein and Ebola virus glycoprotein. This project, funded by the National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health (NIH), aims to identify an optimal adjuvant formulation capable of potentiating both humoral and cell-mediated immunity to protein antigens, compatible with lyophilization and resulting in a thermostabilized vaccine utilizing generally regarded as safe ('GRAS') excipients. Additionally, Soligenix, Inc. has received funding from the National Institute of Dental and Craniofacial Research (NIDCR) within NIH for a cooperative agreement focused on the treatment of oral mucositis in the pediatric population. Furthermore, the company has provided sub-award support to the University of Pennsylvania for a clinical trial evaluating the efficacy of a synthetic hypericin ointment in the treatment of cutaneous T-cell lymphoma (CTCL), specifically mycosis fungoides (MF). This sub-award involves activities such as GMP drug substance and drug product manufacturing, electronic data capture, clinical data management, statistical analysis, and patient enrollment across multiple study sites.

Quick answers

Is Soligenix, Inc. registered in SAM.gov?

Yes. Soligenix, Inc.'s SAM.gov registration is active through July 14, 2027.

What is Soligenix, Inc.'s most recent federal award?

Soligenix, Inc.'s most recent federal grant award is Thermostabilized subunit glycoprotein vaccine platform: immune characterization of an emulsified adjuvant with… (R44AI157593), from National Institute of Allergy and Infectious Diseases (NIH), on December 17, 2020.

On GovTribe

See Soligenix, Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login